Sarepta took a hit from their latest Micro-Dystrophin gene therapy trial update despite showing robust expression in all 4 patients, confirmed by protein analyses and behavioral improvements. In this video, I go through the details of muscular dystrophy, the current treatment options and how this new therapy could significantly improve patients outcomes. I have not taken a position and this is not investment advice. Follow me @matthewlepoire www.breakingbiotech.com Relevant links: https://www.sarepta.com/our-pipeline https://www.sec.gov/Archives/edgar/data/873303/000119312518292068/d616670dex992.htm